Cue Biopharma shares are trading higher after Jefferies initiated coverage on the stock with a Buy rating and $6 price target.
Portfolio Pulse from Benzinga Newsdesk
Cue Biopharma's stock price increased following Jefferies' initiation of coverage with a Buy rating and a $6 price target.
March 13, 2024 | 1:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cue Biopharma's stock price is likely to experience a short-term increase following the positive analyst coverage from Jefferies, which includes a Buy rating and a $6 price target.
Analyst ratings, especially from reputable firms like Jefferies, can significantly influence investor sentiment and stock prices. The initiation of coverage with a Buy rating and a specific price target provides a positive outlook for Cue Biopharma, likely leading to increased investor interest and a rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100